Human Oncology & Pathogenesis Program

The Michael Berger Lab

Michael F. Berger, PhD

Co-Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology; Attending, Molecular Diagnostics Service, Department of Pathology

Professor

The focus of the Berger laboratory is to use novel computational and experimental techniques to characterize the spectrum of genetic mutations in human tumors in order to identify biomarkers of cancer progression and drug response.

The identification of molecular drivers of cancer and the development of targeted therapies for these drivers offer hope for better outcomes for patients with cancer. Global efforts to comprehensively characterize the genomes of all major cancer types continue to reveal new genetic alterations with implications for tumor biology, prognosis, and treatment. Using massively parallel next-generation DNA sequencing, we are developing and applying methods of profiling individual tumor specimenspatient biospecimens for somatic base mutations and other genomicand inherited alterations that may influence response to therapy. Our research falls into two main categories: technology development and biomarker discovery.

View Lab Overview

Featured News

In the Lab

How Do Inherited Gene Mutations Cause Cancer? A New Database Will Help Researchers Find Out

Friday, November 5, 2021

In a new paper, a collaborative team of MSK experts reports how a novel tool will help researchers learn more about the role of inherited hereditary mutations.

Feature

How a Cutting-Edge Liquid Biopsy for Cancer Was Created at MSK

Thursday, July 1, 2021

MSK-ACCESS, a blood test that can detect mutations in 129 genes related to cancer, has already helped guide the treatment of more than 2,800 patients at MSK.

Finding

Machine Learning May Help Classify Cancers of Unknown Primary

Thursday, November 14, 2019

MSK investigators report a new tool that may help them determine the origin of some metastatic tumors, potentially leading to better targeted treatments.

View All Featured News

Publications

Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan SS, Richards AL, Penson AV, Bielski CM, Fong C, Syed A, Jayakumaran G, Prasad M, Hwee J, Sumer SO, de Bruijn I, Li X, Gao J, Schultz N, Cambria R, Galle J, Mukherjee S, Vijai J, Cadoo KA, Carlo MI, Walsh MF, Mandelker D, Ceyhan-Birsoy O, Shia J, Zehir A, Ladanyi M, Hyman DM, Zhang L, Offit K, Robson ME, Solit DB, Stadler ZK, Berger MF, Taylor BS. The context-specific role of germline pathogenicity in tumorigenesis. Nat Genet. 2021 Nov;53(11):1577-1585. doi: 10.1038/s41588-021-00949-1. Epub 2021 Nov 5.

Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. Penson A, Camacho N, Zheng Y, Varghese AM, Al-Ahmadie H, Razavi P, Chandarlapaty S, Vallejo CE, Vakiani E, Gilewski T, Rosenberg JE, Shady M, Tsui DWY, Reales DN, Abeshouse A, Syed A, Zehir A, Schultz N, Ladanyi M, Solit DB, Klimstra DS, Hyman DM, Taylor BS, Berger MF. JAMA Oncol. 2019 Nov 14.

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Nature Medicine. 2017; 23(6):703-713.

Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF*, Mellinghoff IK*. Nature. 2019 Jan;565(7741):654-658.

Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, Berger MF, Zehir A, Ladanyi M, Solit DB, Arnold AG, Stadler ZK, Mandelker D, Goldberg ME, Chmielecki J, Pourmaleki M, Ogilvie SQ, Chavan SS, McKeown AT, Manne M, Hyde A, Beal K, Yang TJ, Nolan CP, Pentsova E, Omuro A, Gavrilovic IT, Kaley TJ, Diamond EL, Stone JB, Grommes C, Boire A, Daras M, Piotrowski AF, Miller AM, Gutin PH, Chan TA, Tabar VS, Brennan CW, Rosenblum M, DeAngelis LM, Mellinghoff IK, Taylor BS. Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clin Cancer Res. 2019 Sep 15;25(18):5537-5547. doi: 10.1158/1078-0432.CCR-19-0032. Epub 2019 Jul 1. PMCID: PMC6753053.

View All Publications

People

Michael F. Berger, PhD

Co-Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology; Attending, Molecular Diagnostics Service, Department of Pathology

Professor

Researcher Michael Berger focuses on massively parallel sequencing of tumor DNA for biomarker discovery and clinical diagnostics.
PhD, Harvard University

[email protected]: Email Address
646-888-3386: Office Phone
View physician profile: Physician profile

Members

Chaitanya Bandlamudi, PhD — Chaitanya Bandlamudi
Assistant Lab Member

Kanika Arora

Senior Computational Biologist

Mukta Asnani
Senior Research Assistant, CMO Technology Innovation

Viswatej Avutu

Fellow

David Brown

Senior Computational Biologist, CMO Technology Innovation

Eric Buehler

Bioinformatics Software Engineer, CMO Cell-Free DNA Informatics

Karmelina Charalambous
Computational Biologist, CMO Cell-Free DNA Informatics

Sebastià Franch Exposito
Research Scholar

Caryn Hale

Senior Computational Biologist, CMO Technology Innovation

Brian Houck- Loomis, Manager, CMO Technology Innovation — Brian Loomis
Head of CMO Technology Innovation

Miika Mehine

Research Fellow

Fanli Meng
Research Lab Manager, CMO Technology Innovation

Kamal Menghrajani

Assistant Attending

Ronak Shah
Lead Scientist, CMO Cell-Free DNA Informatics

Karthigayini Sivaprakasam

Senior Computational Biologist, CMO Cell-Free DNA Informatics

Shalabh Suman
Principal Computational Biologist

Grittney Tam
Senior Research Assistant, CMO Technology Innovation

Alyssa Vann

Bioinformatics Software Engineer, CMO Cell-Free DNA Informatics

Giang Vo

Research Assistant, CMO Technology Innovation

Lab Alumni

Angela Rose Brannon, PhD — Angela Rose Brannon
Research Fellow

Niedzica Camacho-Ordonez
Research Fellow

Adrian Fraiha
Bioinformatics Software Engineer, cfDNA Informatics

Maysun Hasan, Computational Biologist, CMO Technology Innovation — Maysun Hasan
Computational Biologist, CMO Technology Innovation

Xiaohong Jing
Lab Manager, CMO Technology Innovation

Ian Johnson, Bioinformatics Engineer — Ian Johnson
Bioinformatics Engineer, CMO Technology Innovation

Charles Murphy

Senior Computational Biologist, cfDNA Informatics

Juber Ahamad Patel
Computational Biologist, CMO Technology Innovation

Dilmi Perera, Research Fellow — Dilmi Perera
Research Fellow

Johnathan Rafailov

Bioinformatics Tech

Jonathan Reichel
Computational Biologist, CMO Technology Innovation

Jiabin Tang
Group Leader, Innovation Laboratory

Helen Won, MS — Helen Won
Computational Biologist

Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

Career Opportunities

Apply now

Get in Touch

[email protected]

Lab Head Email
646-888-3386

Office Phone
Twitter Profile

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Michael F. Berger discloses the following relationships and financial interests:

Advances in Genome Biology and Technology (AGBT)
Provision of Services (uncompensated)
American Society of Clinical Oncology (ASCO)
Provision of Services
Eli Lilly and Company
Provision of Services
JCO Precision Oncology
Provision of Services (uncompensated)

Journal of Molecular Diagnostics
Provision of Services (uncompensated)
Journal of Visualized Experiments
Provision of Services (uncompensated)
PetDx, Inc.
Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures